The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Dyne Therapeutics Inc (NASDAQ: DYN) closed at $20.61 down -5.89% from its previous closing price of $21.9. In other words, the price has decreased by -$5.89 from its previous closing price. On the day, 1.6 million shares were traded. DYN stock price reached its highest trading level at $21.58 during the session, while it also had its lowest trading level at $20.55.
Ratios:
For a deeper understanding of Dyne Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.47 and its Current Ratio is at 13.47. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.17.
On August 25, 2025, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $35. On June 24, 2025, Bernstein started tracking the stock assigning a Mkt Perform rating and target price of $13.Bernstein initiated its Mkt Perform rating on June 24, 2025, with a $13 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 05 ’25 when Cox John sold 2,640 shares for $13.41 per share. The transaction valued at 35,402 led to the insider holds 199,539 shares of the business.
Friedl-Naderer Johanna sold 894 shares of DYN for $11,863 on Sep 04 ’25. The Chief Commercial Officer now owns 95,017 shares after completing the transaction at $13.27 per share. On Sep 05 ’25, another insider, Friedl-Naderer Johanna, who serves as the Chief Commercial Officer of the company, sold 144 shares for $13.41 each. As a result, the insider received 1,931 and left with 94,873 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DYN now has a Market Capitalization of 2943617024 and an Enterprise Value of 2272195840.
Stock Price History:
The Beta on a monthly basis for DYN is 1.30, which has changed by -0.22257721 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, DYN has reached a high of $31.29, while it has fallen to a 52-week low of $6.36. The 50-Day Moving Average of the stock is 16.29%, while the 200-Day Moving Average is calculated to be 58.75%.
Shares Statistics:
For the past three months, DYN has traded an average of 2.61M shares per day and 2429190 over the past ten days. A total of 142.61M shares are outstanding, with a floating share count of 104.93M. Insiders hold about 26.53% of the company’s shares, while institutions hold 83.58% stake in the company. Shares short for DYN as of 1763078400 were 17111938 with a Short Ratio of 6.56, compared to 1760486400 on 17097410. Therefore, it implies a Short% of Shares Outstanding of 17111938 and a Short% of Float of 13.370000000000001.
Earnings Estimates
Current recommendations for the stock of the company come from 10.0 analysts. The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.75 and low estimates of -$1.0.
Analysts are recommending an EPS of between -$3.39 and -$3.83 for the fiscal current year, implying an average EPS of -$3.57. EPS for the following year is -$3.43, with 12.0 analysts recommending between -$3.08 and -$4.32.
